LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Balance Sheet

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Cash & Equivalents	0.92	0.12	0.2
Cash & Short-Term Investments	0.92	0.12	0.2
Cash Growth	372.11%	-38.01%	-
Other Receivables	0.05	-	0.01
Receivables	0.05	-	0.01
Total Current Assets	1.04	0.12	0.2
Total Assets	1.14	0.12	0.2
Accounts Payable	0.08	0.2	0.04
Short-Term Debt	-	-	0.19
Total Current Liabilities	0.08	0.2	0.23
Total Liabilities	0.08	0.2	0.23
Common Stock	3.29	0.3	0
Retained Earnings	-2.95	-0.45	-0.03
Comprehensive Income & Other	0.73	0.07	-
Shareholders' Equity	1.06	-0.08	-0.03
Total Liabilities & Equity	1.14	0.12	0.2
Total Debt	-	-	0.19
Net Cash (Debt)	0.92	0.12	0
Net Cash Growth	1122779.27%	147336.58%	-
Net Cash Per Share	0.04	0.02	0.01
Filing Date Shares Outstanding	27.69	18.95	0.01
Total Common Shares Outstanding	27.69	19	0.01
Working Capital	0.96	-0.08	-0.03
Book Value Per Share	0.04	-0.00	-2.11
Tangible Book Value	0.96	-0.08	-0.03
Tangible Book Value Per Share	0.03	-0.00	-2.11

Source: S&P Global Market Intelligence. Standard template. Financial Sources.